105 results about "Tissue biopsy" patented technology

The utility model discloses oral mucosa tissue biopsy sampling forceps which comprise a main body, the main body is of a rod-shaped structure, a groove is formed in one end of the main body, sampling forceps are hinged to the interior of the groove, the sampling forceps are arranged in the groove in a crossed mode, a movable block is movably arranged in the main body, and the movable block is arranged in the main body. A groove is formed in one end of the main body, the sampling clamp is movably arranged in the groove, the movable block is cylindrical, connecting plates are arranged on the surface of one end, close to the sampling clamp, of the movable block, the number of the connecting plates is two, the two connecting plates are symmetrically arranged, and a connecting rod is movably arranged between the connecting plates. The movable block is movably arranged in the main body and is connected with the sampling forceps through the connecting rod, and the sampling forceps are driven to open and close by controlling the movable block to move, so that the main body can be arranged into any shape so as to be convenient for medical personnel to operate, thereby improving the efficiency and reducing the sampling difficulty.

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.

The invention concerns methods for predicting changes in a tissue, comprising obtaining snap shot information on individual cells of at least one cell type in a section of a tissue biopsy, wherein the information comprises: (i) spatial localization, (ii) cell type and (iii) cell division state at a specific point in time; calculating cell division probabilities for each of said individual cells; determining cell population dynamics based on the cell division probabilities and predicting future changes in the tissue based thereon. Particularly, the method concerns predicting tissue dynamics in cancer biopsies relevant for prognosis, and assessment of response to therapy.

The invention discloses a marker for predicting the curative effect of tumor immunotherapy as well as application and a detection method of the marker, and belongs to the technical field of biomedicine. The marker is glycerophosphorylcholine (GPC) in peripheral blood, and under the condition that the GPC level of peripheral plasma is low, it is judged that ICIs immunotherapy is poor in curative effect response. Peripheral blood samples are simple and noninvasive to obtain, longitudinal curative effect monitoring can be realized, the method is independent of tissue biopsy and is not influenced by tumor heterogeneity, the cost is reduced, and application is facilitated; meanwhile, peripheral blood not only objectively reflects the systematic immune state of a host, but also is closely related to tumor immunity as an important ring in a tumor immune cycle, and in the aspect of accuracy, the efficiency of a prediction model constructed by GPC reaches 0.886 and is remarkably higher than that of PDL1.

The invention discloses stomach wall tissue biopsy forceps under a laparoscope, and belongs to the technical field of medical instruments. The biopsy forceps aim at solving the problems that existing biopsy forceps are low in sampling efficiency and inconvenient in angle adjustment. The device comprises a fixed pipe and a rotating pipe, a first pull rod is slidably connected into the fixed pipe, a second pull rod is slidably connected into the rotating pipe, an extension column is integrally formed at one end of the second pull rod, a limiting ball is integrally formed at one end of the extension column, and a limiting groove matched with the extension column and the limiting ball is formed in one end of the first pull rod; a connecting part is arranged between the fixed pipe and the rotating pipe and is used for connecting the fixed pipe and the rotating pipe; biopsy forceps are installed at the end, away from the fixed tube, of the rotating tube, and the biopsy forceps and the rotating tube rotate through a connecting part. The driving part is arranged at one end of the fixing tube and used for driving the first pull rod to move, a plurality of samples can be taken through one-time insertion, angle adjustment is flexible, operation is labor-saving, and the device is used for stomach wall tissue sampling under a laparoscope.

The present application relates to the field of medical equipment, and in particular to an endoscopic imaging device, an imaging system, and a method thereof having a diagnostic imaging device. The device comprises: a diagnostic imaging device, an external control device, and an ingestible capsule endoscope. The external control device is used to control the position and / or posture of the capsule endoscope within a target area; the diagnostic imaging device is disposed within the capsule endoscope and is used to perform diagnostic imaging of the target area under the control of the external control device. The endoscopic imaging device and the imaging method thereof provided in the present application utilize a diagnostic imaging device to examine the target area without the need for a tissue biopsy, thereby not only improving the accuracy of the examination of the lesion area, but also reducing the risk of infection in the patient.

A method of sampling a target tissue in an animal body, comprising the steps of inserting a endoscope-needle system into the animal body, guiding the endoscope-needle system along a path toward the target tissue using a Doppler-based optical coherence tomography (OCT) system coupled with machine-learning-based computer-aided diagnosis (ML-CAD), wherein the Doppler-based OCT system coupled with ML-CAD enables the identification of blood vessels along the path in advance of the needle tip of the endoscope-needle system thereby substantially avoiding damage to the blood vessels along the path as the needle tip of the endoscope-needle system is guided into the target tissue, after the needle tip is guided into the target tissue, and removing a tissue sample from the target tissue.

The utility model relates to the field of temporary storage devices, in particular to a pathological tissue biopsy temporary storage device. The utility model provides a pathological tissue biopsy temporary storage device which can eject pathological tissues out of a temporary storage cylinder and is convenient for workers to take. A pathological tissue biopsy temporary storage device comprises a temporary storage barrel, a first spring, a mounting frame and a storing and taking mechanism, the middle of the temporary storage barrel is slidably and rotatably connected with the mounting frame, the first spring is connected between the mounting frame and the temporary storage barrel through a gasket, and the storing and taking mechanism capable of fixing and rapidly taking pathological tissues is arranged on the mounting frame. When diseased tissue needs to be taken out, the limiting piece is pulled to move to be separated from the upper portion of the mounting frame, so that the first spring rebounds, the mounting frame is driven to move upwards, the diseased tissue moves upwards, and the effects that the diseased tissue can be ejected out of the temporary storage barrel, and workers can take the diseased tissue conveniently are achieved.

The utility model discloses a pair of multi-angle adjustable endoscopic biopsy forceps, and relates to the technical field of medical instruments, in particular to a pair of multi-angle adjustable endoscopic biopsy forceps which comprises a handle assembly, an inner sliding groove is formed in the middle of the handle assembly, and a rack buckle is arranged above the handle assembly. One side of the rack buckle is in sliding connection with a pliers movable traction block, the other side of the rack buckle is in sliding connection with a pliers rotating traction block, and a transition connecting sleeve is fixedly installed at the end of the handle assembly. According to the multi-angle adjustable endoscopic biopsy forceps, the front head bend, the rotating cylinder and the forceps mounting shaft are arranged in a matched mode, so that the multi-angle adjustable endoscopic biopsy forceps have the effects that the head end can independently rotate, tissue biopsy can be better carried out, and the efficiency is improved; therefore, the multi-angle adjustable endoscopic biopsy forceps have the effect of conveniently controlling the bending of the tail end of the biopsy forceps.

Provided herein, among other things, is a method of treating a cancer patient without the need for a tissue biopsy. In some embodiments, the method may comprise (a) performing or having performed a sequencing assay on cell-free DNA (cfDNA) from a sample of blood from the patient to determine if the cell-free DNA comprises actionable and / or non-actionable sequence variations in one or more target genes, and (b) treating the patient using the following method: i. administering a therapy that is targeted to an actionable sequence variation if the patient is identified as having the actionable sequence variation, and ii. administering a non-targeted therapy in the absence of any follow-up genetic testing on DNA extracted from a tissue biopsy if one or more non-actionable sequence variations and no actionable sequence variations are identified.

The invention relates to an application of maximum allele mutation abundance in prediction of a mismatch repair protein complete metastatic colorectal cancer immunotherapy effect. The invention particularly relates to application of the maximum allele mutation abundance and a reagent or system for detecting the maximum allele mutation abundance in preparation of a system for predicting the immunotherapy effect of the mismatch repair protein complete metastatic colorectal cancer. According to the method, the baseline ctDNA maxVAF is used as the immunotherapy curative effect prediction marker for the first time, the blank in the field is filled, clinical individualized treatment, use of a peripheral blood sample and calculation of the maximum allele mutation abundance of peripheral blood circulation are better guided, sample acquisition is convenient, invasive tissue biopsy is not needed, and patient acceptance is high.

Methods are provided for detecting gene deletions and driver mutations using tumor-specific methylation patterns from cell-free DNA and tissue biopsies. The methods exploit the mutual exclusivity between tumor-specific methylation and homozygous gene deletion, enabling detection through absence of expected methylation signals. Applications include detection of MTAP, PTEN, and RB1 deletions, as well as prediction of EGFR single nucleotide (SNV) and small (up to 50 base pair) insertions and deletions (indel) driver mutations, enabling identification of patients eligible for targeted therapies.

A novel portable, and attachable device allows precise positioning of micro-tissues, tumor spheroids, and other biological samples during bioprinting. The device features an interchangeable connector for handling samples of various sizes and uses a manually adjustable pressure system for suction and deposition. A programmable control unit coordinates pressure and positioning based on input commands, enhancing accuracy and consistency in tissue handling. Compatible with multiple bioprinter systems and supporting both manual and automated operation, it streamlines workflows and improves user experience. This device addresses challenges in high-throughput biological positioning, critical for tissue engineering, clinical, pharmaceutical, and research applications. It supports advancements in customized medicine, biological models, and environmental monitoring, meeting the growing demand for precise biologic handling in the multi-billion-dollar bioprinting and biopsy markets. The device offers superior control over tissue biopsy positioning compared to current manual devices reliant on operator skill.

The present invention provides a method and application for predicting breast cancer metastasis. The present invention uses body fluid exosomes as samples, utilizes liquid chromatography tandem mass spectrometry, obtains the protein phenotype of patients with breast cancer metastasis, establishes a metastasis diagnosis model based on proteomics, and provides a kit or chip for detecting breast cancer lymph node metastasis, and the application of breast cancer lymph node metastasis protein markers in the preparation of kits and / or chips. Compared with traditional diagnostic methods such as axillary lymph node dissection and tissue biopsy, the present invention has the characteristics of non-invasive and convenient detection, and can accurately determine whether the sample to be tested is a breast cancer metastasis sample.

The invention provides a nucleic acid aptamer specifically combined with endometriosis cells and application of the nucleic acid aptamer, and belongs to the technical field of biology. The nucleic acid aptamer capable of being specifically combined with the endometriosis cells is screened out through the Cell-SELEX technology with living cells as screening objects, and the nucleic acid aptamer has the advantages of being high in specificity, high in affinity, high in specificity, high in specificity and high in specificity. The probe can be used for early diagnosis of endometriosis, tissue biopsy, ectopic endometrial tissue excision guided by fluorescence, targeted drug development and the like.

The invention discloses a cardiovascular lesion tissue biopsy sampling device, and relates to the technical field of biopsy sampling, the cardiovascular lesion tissue biopsy sampling device comprises a cannula, a cannula body is fixed in the cannula, and the cannula and the cannula body are provided with gaps; the piston plate is arranged in the pipe body in a sliding mode, and a plurality of round holes are formed in the side wall of the piston plate; the sealing assembly is in sliding connection with the piston plate, and the sealing assembly is used for sealing the circular hole; and the supporting assembly is fixed in the pipe body, and the supporting assembly is connected with the piston plate. By means of movement of the piston plate and cooperation with work of the sealing assembly, negative pressure can be generated at the notch so that diseased tissue can enter the tube body through the notch, normal saline can be injected into the middle end of the tube body through the supporting assembly and the transmission assembly, the cut diseased tissue can be output out of the tube body, and therefore the diseased tissue can be conveniently cut. And the next sampling work can be carried out.

Various embodiments may relate to a tissue biopsy instrument according to various embodiments. The tissue biopsy instrument may include a hollow tube having a distal end portion and a proximal end portion. The tissue biopsy instrument may further include a cutting device held within a distal end portion of the hollow tube.

The invention provides a genome kit capable of identifying and diagnosing pulmonary nodules, which comprises the following steps: taking 21-gene panel as a molecular marker, detecting and calculating tumor mutation load of 21-gene in peripheral blood of a pulmonary nodule patient by adopting EV DNA in the peripheral blood, and calculating the tumor mutation load of 21-gene in the peripheral blood of the pulmonary nodule patient. A benign and malignant pulmonary nodule diagnosis scoring system is established by combining four clinical factors (gender, smoking condition, age and nodule diameter), and malignant pulmonary nodules are identified and diagnosed according to diagnosis scores. The 21-gene panel is used as the molecular marker for judging benign and malignant pulmonary nodules, and compared with CT and tissue biopsy, the 21-gene panel has more remarkable recognition and prediction value on malignant pulmonary nodules and has important guiding significance for judging the progression of tumors to invasive adenocarcinoma.

Methods for determining genomic variant clonality using multi-region sequencing assays and algorithms are described. For example, the methods can include receiving, at one or more processors, sequence read data for a sample obtained from a subject. The sequence read data is obtained from nucleic acid molecules (extracted, e.g., via needle punch) from a plurality of target regions within the sample (e.g., spatially distinct regions of a tissue biopsy sample). For each target region within the sample, a set of reads from the sequence read data associated with the respective target region is identified, then a presence of a candidate genomic variant within the target region is detected based on the set of reads. A total number of target regions in which the presence of the candidate genomic variant is compared to a first predetermined threshold. Based on the comparison, clonality of the candidate genomic variant is determined.

The present invention provides a method for detecting benign and malignant breast tumors and its application. Taking body fluid exosomes as samples, the present invention uses liquid chromatography tandem mass spectrometry to obtain the protein phenotypes of patients with benign and malignant breast tumors, establish a detection and / or prediction model for benign and malignant breast tumors based on proteomics, and provides a kit or chip for detecting benign and malignant tumors, as well as the application of protein markers for benign and malignant breast tumors in the preparation of the kit and / or chip. Compared with traditional detection methods such as tissue biopsy, the present invention has the characteristics of non-invasive and convenient detection, and can accurately distinguish whether the sample to be detected is a sample of benign or malignant breast tumor.

The utility model discloses an umbrella opening type pleura biopsy device, which relates to the field of pleura tissue biopsy, and comprises an inner sleeve, an annular groove, a needle cylinder groove and a hook-shaped groove which are distributed in the inner sleeve from top to bottom, and a push rod which is assembled in the inner sleeve in a sliding manner, through the designed limiting unit, fastening unit and sampling unit, in the process of obtaining a pleural tissue sample, the limiting unit is used for limiting the push rod and controlling the push rod to slide in the puncture needle, so that the sampling is more convenient; meanwhile, the to-be-sampled part and the biopsy device are stabilized under the action of the fastening unit, so that the instrument is prevented from shaking in the sampling process; and finally, under the action of the sampling unit, umbrella-shaped sampling can be performed on the sample, so that the condition that the sampling is incomplete or the sample is not taken is avoided, and great clinical significance is achieved.

The invention relates to a non-invasive vagina examination treatment device which comprises a handheld shell, a visual collection tube, a control bin and a flushing sleeve, an end mounting seat is arranged at the working end of the visual collection tube, a picture collection camera is arranged in the end mounting seat, an LED annular lamp is arranged on the peripheral side of the picture collection camera, and the LED annular lamp is connected with the visual collection tube. A flushing interlayer is formed between the flushing sleeve and the visual collection tube, and one of a secretion extraction assembly, a tissue biopsy extraction assembly, a foreign matter clamping assembly and a negative pressure suction assembly is arranged at the working end of the visual collection tube. The visual collection tube enters the vagina from the vaginal orifice of a patient to achieve real-time collection of images in the vagina, different operation assemblies are installed at the front end of the visual collection tube in a matched mode, secretion extraction, tissue biopsy extraction, foreign matter clamping and other operations are achieved, the diameter of the whole device does not exceed 0.7 cm, and the visual collection tube is used for collecting the images in the vagina. The principle of minimum invasion can be met as much as possible, and the discomfort of a patient is effectively reduced.

The application discloses a low-noise pneumatic air gun type biopsy needle convenient for single-hand loading, which comprises an inner needle, an outer needle, a connector, a mechanical valve, a firing mechanism, a loading mechanism, a needle cylinder, a needle cylinder shell, a first piston, a tension spring, a second piston and a compression spring. The inner needle is glued on the outer side of the front end of the needle cylinder, the outer needle is glued on one end of the connector and is sleeved on the outer side of the inner needle, and the other end of the connector is fixed with the elongated part of the second piston. The needle cylinder comprises a needle cylinder part one and a needle cylinder part two, and the needle cylinder and the needle cylinder shell are bonded into an integrated whole after being aligned. The second piston is fixedly connected with the compression spring and is located on the inner side of the front end of the needle cylinder, and the other end of the compression spring is sleeved on the protruding part on the inner side of the front end of the needle cylinder. The first piston is fixedly connected with the tension spring and is located on the inner side of the tail end of the needle cylinder, and the other end of the tension spring is bonded with the tail seat of the needle cylinder. The firing mechanism realizes button control of cutting and sampling of the outer needle. The loading mechanism realizes button control of returning and loading of the outer needle. The application reduces the dependence of surgical operation on the experience of doctors, reduces the noise generated in the surgical process, avoids the body displacement of patients due to the noise, improves the precision of tissue biopsy surgery, can realize single-hand operation and improves the convenience of surgical operation.

The invention relates to the technical field of biological medicine, in particular to application of an lnc81 related reagent in ovarian function impairment related products. The invention provides an application of an lnc81 related reagent in ovarian function impairment related products, and provides a new biomarker for detecting ovarian function impairment, the biomarker is lnc81, and by using the marker, the false positive risk can be reduced, the detection accuracy is improved, the trauma of tissue biopsy is avoided, and the risk of ovarian function impairment is reduced. The method is suitable for dynamically monitoring curative effect or relapse.

Among the various aspects of the present disclosure is the provision of a noninvasive and localized brain liquid biopsy using focused ultrasound. Briefly, therefore, the present disclosure is directed to methods and systems to identify brain lesion or tumor characteristics without the need for a solid brain biopsy.

The present invention relates to a novel vertebral bone tissue biopsy instrument, comprising a cutting assembly, an adjusting assembly and an outer tube assembly which are sequentially sleeved from the inside to the outside, wherein the cutting assembly comprises a cutting piece and a handle, wherein the proximal end of the cutting piece is fixedly connected to the handle, wherein the adjusting assembly comprises an adjusting tube and an adjusting handle, wherein the proximal end of the adjusting tube is fixedly connected to the adjusting tube handle, and by operating the adjusting tube handle, the adjusting tube can slide axially along the cutting piece to realize the recovery and release of the distal end of the cutting piece, and the outer tube assembly comprises an outer tube and an outer tube handle, wherein the proximal end of the outer tube is fixedly connected to the outer tube handle, and by operating the outer tube handle, the outer tube can move axially with the adjusting tube and the cutting piece.

Provided herein, among other things, is a method of treating a cancer patient without the need for a tissue biopsy. In some embodiments, the method may comprise (a) performing or having performed a sequencing assay on cell-free DNA (cfDNA) from a sample of blood from the patient to determine if the cell-free DNA comprises actionable and / or non-actionable sequence variations in one or more target genes, and (b) treating the patient using the following method: i. administering a therapy that is targeted to an actionable sequence variation if the patient is identified as having the actionable sequence variation, and ii. administering a non-targeted therapy in the absence of any follow-up genetic testing on DNA extracted from a tissue biopsy if one or more non-actionable sequence variations and no actionable sequence variations are identified.

This invention relates to a high precision biopsy instrument which is self-cutting and self-retrieval in nature and includes a camera and a fiber-optic light configured for obtaining the biopsy tissue. The biopsy instrument with the incorporation of vertical and horizontal cutting blades is configured to obtain the biopsy tissue with minimum architectural tissue damage. The camera in the biopsy instrument is used to facilitate capturing photographs of the potentially malignant disorders and malignant neoplasms for the purpose of diagnosis as well as video graph the same for the purpose of determining the exact site of biopsy through tele-conferencing between surgeons and pathologists. The pictures obtained during the procedures can be used for documentation purpose. The present invention also includes a fiber optic light for illumination of the operating site as it creates less colour variation.

Eleven percent of all men will develop prostate cancer (PC). In the US, 3 million men are living with the disease, 192,000 new cases are expected, and 33,000 men will die from the illness this year. PC is the second leading cause of cancer (CA) deaths in men worldwide, the diagnosis of PC relies on a combination of tests and procedures, including the digital rectal exam (DRE), magnetic resonance imaging (MRI), ultrasound, and multiple tissue biopsies, each with escalating costs and risks. In 2018, the cost of PC care in the US was $15.3 billion dollars, of which $5.7 billion was spent on diagnosis and $8.3 billion on management. There is a critical need for an early, accurate, reliable and cancer specific diagnostic for PC. The technology as described herein relates to compositions and methods for diagnosing and staging of cancer in a subject.

The invention provides methods for assessment of tumor biomarkers using target-enriched multiplexed parallel analysis. The methods of the invention utilize Target Capture Sequences (TACS) to thereby enrich for target sequences of interest, followed by massive parallel sequencing and statistical analysis of the enriched population. The methods can be used with DNA samples from a patient, such as a tissue biopsy or plasma sample (liquid biopsy), for detection of the presence of tumor biomarkers, e.g., for purposes of diagnosis, screening, therapy selection and / or treatment monitoring. Kits for carrying out the methods of the invention are also provided.